To harness the potent ability of Flt3L to expand cross-presenting DCs and albumin to extend half-life while preferentially trafficking to the LNs and tumor, we generated an immunotherapeutic molecule, Alb-Flt3L, by genetically fusing albumin to Flt3L (Supplemental Figure 1, A–D; supplemental material available online with this article; https://doi.org/10.1172/JCI171621DS1). This evidence concerns the gene FLT3LG and neoplasm.